ZEUS – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Multiple Locations

Overview 

The purpose of this study is to determine if the medication ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease and chronic kidney disease. 

Eligibility Criteria 

  • Ages 18 and older 
  • Diagnosis of chronic kidney disease defined by one of the below: 
    • Estimated glomerular filtration rate (eGFR) great than or equal to 15 and below 60 mL/min/1.73 m^2. 
    • Urinary albumin-to-creatinine ration (UACR) greater than or equal to 200 mg/L.
  • Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 mg/L.
  • Evidence of atherosclerotic cardiovascular disease (ASCVD) 
    • Coronary heart disease
    • Cerebrovascular disease
    • Peripheral Artery Disease (PAD)

Additional inclusion/exclusion criteria will apply. 

Participation

Participants will either receive ziltivekimab (active medicine) or placebo in a pre-filled syringe and will need to inject into a skinfold once monthly. Participation will last for up to 4 years with participants having up to 20 clinic visits which will consist of blood and urine collections, and ECG. 

Contact 

Novo Nordisk

Locations

United States 

  • Alabama 
  • Arizona 
  • Arkansas 
  • California 
  • Colorado 
  • Connecticut 
  • District of Columbia 
  • Florida 
  • Georgia 
  • Idaho 
  • Illinois 
  • Indiana 
  • Kansas 
  • Kentucky 
  • Louisiana 
  • Maryland 
  • Massachusetts 
  • Michigan 
  • Minnesota 
  • Missouri 
  • Nebraska 
  • Nevada 
  • New Jersey 
  • New Mexico 
  • New York 
  • North Carolina 
  • North Dakota 
  • Ohio 
  • Pennsylvania 
  • Rhode Island 
  • South Carolina 
  • Tennessee 
  • Texas 
  • Utah 
  • Virginia 
  • Washington 
  • Wisconsin